Supported via arm's length funding from Novo Nordisk

Highlights from

EASD 2019

55th Annual Meeting of the European Association for the Study of Diabetes

Barcelona, Spain 16 - 20 September 2019
SCROLL TO ARTICLES

Professor Hertzel Gerstein (REWIND)

In this podcast, Professor Hertzel Gerstein, Endocrinologist at McMaster University, Canada discusses results from the REWIND trial, describing cardiovascular outcomes for patients with type 2 diabetes treated with dulaglutide and how these results compare with data from other GLP-1 receptor agonist cardiovascular outcome trials.

Professor Hertzel Gerstein’s disclosures:
Research funding: Eli Lilly, AstraZeneca, Merck, Novo Nordisk, Sanofi.
Consulting/ advisory boards/ speaker: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Janssen Pharmaceuticals, Sanofi, Kowa Pharmaceuticals, Cirius Therapeutics.

Articles

Recent advances in diabetes management

Top image: @ iStockPhoto: Kwangmoozaa

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

Supported by